Pretreatment Glasgow prognostic score predicts survival among patients with high PD‐L1 expression administered first‐line pembrolizumab monotherapy for non‐small cell lung cancer. (20th August 2021)

• Record Type: Journal Article
• Authors: Imai, Hisao; Kishikawa, Takayuki; Minemura, Hiroyuki; Yamada, Yutaka; Ibe, Tatsuya; Yamaguchi, Ou; Mouri, Atsuto; Hamamoto, Yoichiro; Kanazawa, Kenya; Kasai, Takashi; Kaira, Kyoichi; Kaburagi, Takayuki; Minato, Koichi; Kobayashi, Kunihiko; Kagamu, Hiroshi
• Is Part Of: Cancer medicine. Volume 10:Number 20(2021)
• Page Start: 6971
• Page End: 6984
• Publication Date: 2021-08-20
• Subjects: body mass index -- Glasgow prognostic score -- non‐small cell lung cancer -- pembrolizumab; 616.994005
• DOI: 10.1002/cam4.4220
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: There are no established biomarkers for predicting the efficacy of first‐line pembrolizumab monotherapy in patients with high programmed death‐ligand 1 (PD‐L1) expression. In this study, we investigated whether the Glasgow prognostic score (GPS), neutrophil‐to‐lymphocyte ratio (NLR), and body mass index (BMI) can be used to evaluate the effect of first‐line pembrolizumab monotherapy in patients with advanced non‐small cell lung cancer (NSCLC) who express high levels of PD‐L1. Methods: We reviewed data from 142 patients with high PD‐L1 expression who underwent first‐line pembrolizumab monotherapy for NSCLC at six Japanese institutions between February 2017 and June 2019 and assessed the prognostic value of the GPS, NLR, and BMI. The Kaplan–Meier method and Cox proportional hazard models were used to examine differences in progression‐free survival (PFS) and overall survival (OS). The GPS, NLR, and BMI were calculated using C‐reactive protein and albumin concentrations, neutrophil and lymphocyte counts, and body weight and height, respectively. Results: The GPS independently predicted the first‐line pembrolizumab monotherapy efficacy, as a good GPS (GPS 0–1) was associated with a significantly better PFS and OS compared to a poor GPS (GPS 2) (PFS: 11.8 vs. 2.9 months, p < 0.0001; OS: not reached vs. 8.3 months, p < 0.0001). Furthermore, BMI independently predicted efficacy, as patients with high BMI (BMI ≥21.4) exhibited significantly better OS compared to those with low BMI (BMI <21.4) (OS: not reached vs. 14.1 months, p = 0.006). Conclusions: Among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC, the GPS is significantly correlated with both PFS and OS, and BMI with OS, indicating that they could be used to predict treatment outcome in these patients. To the best of our knowledge, this is the first study to assess the relationship among the GPS, NLR, and BMI and survival among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC. Abstract : We investigated whether the Glasgow prognostic score (GPS), neutrophil‐to‐lymphocyte ratio, and body mass index (BMI) can be used to evaluate the effect of first‐line pembrolizumab monotherapy in patients with advanced non‐small cell lung cancer (NSCLC) who express high levels of programmed death‐ligand 1 (PD‐L1). Among patients with high PD‐L1 expression undergoing first‐line pembrolizumab monotherapy for NSCLC, the GPS is significantly correlated with both progression‐free survival and overall survival (OS), and BMI with OS, indicating that they could be used to predict treatment outcome in these patients.